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Purpose: We retrospectively analyzed the treatment outcomes and 
toxicities by hypofractionated three-dimensional conformal radiation 
therapy (RT) alone in the patients with centrally located cT1-3N0 
non–small-cell lung cancer (NSCLC).
Methods: Sixty patients with centrally located cT1-3N0 NSCLC 
received definitive RT alone at 3.0 Gy per fraction for either medi-
cal comorbidity or refusal of surgery, between January 2001 and 
December 2010. The central tumor was defined as being within 2 cm 
around the proximal bronchial tree. The median total dose was 60 
(39–60) Gy.
Results: The local control (LC), overall survival (OS), and cause-
specific survival rates at 2 and 5 years were 57.9%, 59.6%, 61.7%, 
and 50.1%, 33.5%, and 40.5%, respectively. Multivariate analyses 
showed that high cT stage (p = 0.007) and histology with NSCLC-
not otherwise specified (p = 0.008) were the significantly unfavor-
able prognostic factors for OS, and that high cT stage (p = 0.031) 
and poor performance state (p = 0.007) were for LC. The LC rate 
at 2 years was 100% for cT1 tumor, 56.5% for cT2 tumor, and 
28.6% for cT3 tumor, respectively. No patients experienced grade 
3 or higher esophagitis, and three experienced grade 3 or higher 
pneumonitis.
Conclusion: Hypofractionated RT regimen for centrally located 
cT1-3N0 NSCLC proved safe with minimal toxicity, and, based on 
the excellent clinical outcomes in cT1 tumors, might serve as an 
alternative option for the patients who might not tolerate stereo-
tactic body radiation therapy. As the clinical outcomes in cT2-3 
tumors were still unsatisfactory, further dose intensifying regimen 
coupled with the use of concurrent systemic chemotherapy might 
be warranted.
Key Words: Non–small-cell lung cancer, Radiation therapy, Central 
tumors.
(J Thorac Oncol. 2013;8: 624-629)
Surgical resection has been the standard treatment for early-stage non–small-cell lung cancer (NSCLC). For patients who 
are medically inoperable because of medical comorbidity, or who 
decline surgery, however, definitive high-dose radiation therapy 
(RT) is the most appropriate curative alternative. The conven-
tionally fractionated RT delivering 60 to 66 Gy for 6 to 7 weeks 
in daily doses of 1.8 or 2.0 Gy were commonly used. The con-
ventionally fractionated RT, however, is known to achieve rather 
unsatisfactory clinical outcomes: 5% to 42% in 5-year overall 
survival (OS) rates; and 30% to 45% in local control (LC) rates.1,2
Stereotactic body radiation therapy (SBRT) is a spe-
cialized local ablative modality, in which highly focused and 
accurately controlled radiation beams are used to deliver a few 
fractions of very high fractional dose (10–20 Gy) and usu-
ally finishes within a week.3 Recently, the application of SBRT 
to the patients with cT1-2N0 or selected cT3N0 NSCLC has 
become frequent, and has shown very promising clinical out-
comes, with the LC rate of approximately 90% at a very low 
complication rate in many institutes.4–8 The Radiation Therapy 
Oncology Group (RTOG) study, after SBRT with 54 Gy in 
three fractions, showed that the primary tumor control rate 
was 97.6% and the 3-year OS rate was 55.8%.4 The patients 
with centrally located tumors or large-sized tumors, however, 
may not be the ideal candidates for SBRT because of the risk 
of excessive toxicities,2,5,9 although several authors reported 
acceptable toxicity of SBRT for these tumors by dose modifi-
cation with strict constraints for critical structures.10,11
Several institutions have reported favorable results in 
early-stage NSCLC by various hypofractionated regimens, 
which were different from the SBRT dose schedules, in the 
patients who might not tolerate SBRT.12–16 These consist of more 
fractions by lower fractional doses (usually <10 Gy) than the 
SBRT dose schedules. At the author’s institute, high-dose RT by 
daily 3.0 Gy has been used for the patients who are candidates 
of neither surgery nor SBRT, and our early experience of this 
regimen in early-stage NSCLC was previously reported.17 
In the current study, we analyzed the clinical outcomes by 
the abovementioned dosage schedule to the patients having 
centrally located tumors with no evident lymphatic metastasis.
PATIENTS AND METHODS
Patients
From January 2001 till December 2010, 275 NSCLC 
patients received high-dose definitive RT alone because of 
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either medical comorbidity or refusal of surgery at the authors’ 
institute. Among them, 60 patients had centrally located cT1-
3N0 NSCLC and formed the basis of this retrospective study. 
The central tumor was defined as all or part of the gross tumor 
located within the proximal bronchial tree, which includes the 
lobar or greater bronchi plus 2 cm in all directions around. The 
typical cases were presented in Figure 1. Pathologic confir-
mation of NSCLC was made in all patients by bronchoscopy 
or percutaneous fine-needle aspiration and biopsy. The clini-
cal stage was determined according to the 6th American Joint 
Committee on Cancer (AJCC) staging system. The diagnostic 
and staging workups included a complete history-taking and 
physical examination, simple chest radiographs, chest com-
puted tomography (CT) scans (which covered the liver and 
adrenal glands), bronchoscopy, blood tests, bone scans, and 
brain magnetic resonance imaging.18Fluoro-deoxy-glucose 
positron emission tomography (PET) or PET/CT has been 
performed in almost every patient since 2003. As a result, 51 
patients (85%) had PET or PET/CT.
Radiation Therapy
In all the patients, contrast-enhanced CT scans were 
performed in a supine position for simulation of three-dimen-
sional conformal RT. CT images with 2.5 to 5.0 mm thick-
ness were obtained during the quiet respiration. The clinical 
target volume (CTV) was delineated with a 3- to 5-mm mar-
gin in all directions around the gross tumor volume. Planning 
target volume was determined with adding a margin of 1.0 
to 1.5 cm around the CTV to compensate for the respiratory 
movement and the set-up uncertainty. The addition of elec-
tive nodal irradiation (ENI) to the mediastinal lymphatics was 
individually determined per the physician’s discretion, based 
on the clinical tumor size, location, and the histologic grade. 
The radiation dose was prescribed at the isocenter with the tis-
sue heterogeneity corrections. The planned dosage was 60 Gy 
in once-daily 3.0 Gy doses during 4 consecutive weeks. Three 
or four beam arrangements were typically used to adequately 
cover the CTV while minimizing the dose to the normal tis-
sues including the lung, the spinal cord, the heart, and the 
esophagus. The maximum dose to the spinal cord was not to 
exceed 45 Gy. For the lung, V
20
 (percentage of the total lung 
volume irradiated >20 Gy) ≤27.5% and the mean lung dose 
(MLD) of 16 Gy or lesser were preferred.18 However, these 
lung constraints were not absolute requirements.
Follow-Up
The chest CT was performed for the evaluation of the 
initial response in 1 to 2 months of the RT completion, and 
the patients were followed up at 3 to 4 months’ interval there-
after, with either chest CT or whole-body PET/CT. The treat-
ment-related toxicities were graded according to the Common 
Terminology Criteria for Adverse Events, version 3.0.
Statistical Analysis
The survival rates were calculated by the Kaplan–Meier 
method. The duration of LC was from the first day of RT till 
the date of the first occurrence of local failure or the follow-up 
loss. The durations of OS and cancer-specific survival (CSS) 
were calculated from the first day of RT till the date of death 
by all causes or death by cancer progression or the treatment-
related toxicities, respectively. The log-rank test was per-
formed for univariate comparisons between the groups, and 
the Cox proportional hazards regression model was used for 
multivariate analysis. The distribution of categorical variables 
was analyzed by the χ2 test. A p value of 0.05 or less was 
considered statistically significant. SPSS 19.0 (SPSS Inc., 
Chicago, IL) was used for the analysis.
RESULTS
Patient Characteristics
Among 60 patients who had centrally located cT1-3N0 
NSCLC, the reasons for receiving RT alone were medical 
comorbidity in 56 patients (93.3%), and refusal of surgery 
in four (6.7%). The median follow-up period of all patients 
was 18 (1–96) months. Thirty-five patients (58.3%) were 
aged 70 years or older. Thirty-seven patients (61.7%) had 
Eastern Cooperative Oncology Group (ECOG) performance 
status 0 to 1, whereas 23 (38.3%) had ECOG 2. Forty-four 
patients (73.3%) had squamous cell carcinoma. Forty-four 
patients (73.3%) received RT with the total dose of 60 Gy, 
and 14 (23.3%) received 54 Gy. Two patients (3.3%) received 
less than 54 Gy because of poor ECOG performance status. 
One patient stopped at 39 Gy and the other patient at 42 Gy. 
The ENI to the regional lymphatics was added to 19 patients 
(31.7 %), with the median dose of 30 (30–39) Gy. Dosimetric 
parameters of the lung could be obtained from 52 patients. In 
FIGURE 1.  The axial and coronal computed tomography 
images in two patients with centrally-located tumors.
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these patients, the median V
20
 and MLD were 17.6% (6.7%–
33.0%) and 997.5 cGy (454–1,570 cGy), respectively. The 
characteristics of all the patients are summarized in Table 1.
Toxicity
Grade 2 esophagitis occurred in 10 patients (16.7%), 
and none experienced esophagitis of grade 3 or more. Grade 
2 pneumonitis developed in six patients (10.0%), grade 3 in 
two (3.3%), and grade 5 in one (1.7%). The patient who died 
of radiation pneumonitis was an 80-year-old woman, who 
was treated with a total dose of 54 Gy. She had 2.6-cm–sized 
tumor in the left upper bronchus, and the forced expiratory 
volume at 1 second and forced vital capacity were 1.44 liter/
second and 2.51 liters. In 5 months after RT, she complained 
of cough and dyspnea, and the lung haziness within the RT 
volume and pleural effusion were shown on the CT scan. 
She was managed with steroid and her symptoms were wax 
and wane thereafter. In 12 months, her symptoms aggravated 
again and she eventually died of respiratory failure, without 
evidence of cancer progression. The dosimetric parameters of 
V
20
 and MLD were 33% and 15.5 Gy, respectively.
The addition of ENI resulted in increased toxicities of 
grade 2 or higher, although there was no significant statisti-
cal difference. For esophagtis, grade 2 toxicity developed 
in five of 19 patients (26.3%) in ENI (+) group, and in five 
of 41 patients (12.2%) in ENI (−) group (p = 0.126). For 
pneumonitis, grade 2 or higher toxicity developed in five of 19 
patients (26.3%) in ENI (+) group and in four of 41 patients 
(9.8%) in ENI (−) group (p=0.263).
LC and Patterns of Failure
A total of 41 patients (68%) experienced failures. The 
initial relapses were local failure in 19 patients (31.7%), 
regional failure in seven patients (11.7%), and distant metasta-
sis in 20 patients (33.3%), respectively (Fig. 2). Interestingly, 
the addition of ENI resulted in a decrease of regional recur-
rence as the first site of relapse. The regional failures occurred 
in one of 18 patients (5.2%) with ENI, and in six of 41 patients 
(14.6%) without ENI (p = 0.414). The sites of regional recur-
rence in these six patients were supraclavicular lymph node 
(n = 3), paraaortic lymph node (n = 1), paratracheal lymph 
node (n = 1), and hilar lymph node (n = 1).
The actuarial LC rates at 2 and 5 years were 57.9% and 
50.1% (Fig. 3). Univariate analyses were performed on the 
patient age, sex, performance state, histology, total dose of 
radiation, cT stage, and the tumor size for the LC rate. The 
factors that showed a statistical significance on the 2-year 
LC rates included cT stage (100% for T1, 56.5% for T2, and 
28.6% for T3; p = 0.003), tumor size (70.2% for tumor ≤3 cm 
and 46.9% for tumor >3 cm; p = 0.096), and performance 
status (72.9% for ECOG 0–1, 32.1% for ECOG 2; p = 0.002) 
(Fig. 4). Multivariate analysis showed that high cT stage 
(p = 0.031) and poor performance status (p = 0.007) adversely 
affected the LC significantly.
Survival
The median OS and CSS were 33 months and 33 
months (Fig. 3). There were 25 cancer-specific deaths: dis-
ease progression in 21 patients; community-acquired pneu-
monia in three; and radiation pneumonitis in one. There were 
four deaths unrelated to lung cancer: chronic obstructive 
TABLE 1.  Characteristics of All Patients
Characteristic Number of Patients (%)
Age, yr
 <70 25 (41.7)
 ≥70 35 (58.3)
Gender
 Male 49 (81.7)
 Female 11 (18.3)
Performance status
 0–1 37 (61.7)
 2 23 (38.3)
T stage
 T1 10 (16.7)
 T2 33 (55.0)
 T3 17 (28.3)
Tumor size, cm
 ≤3 22 (36.7)
 > 3 38 (63.3)
Histology
 Squamous cell carcinoma 44 (73.3)
 Adenocarcinoma 10 (16.7)
NSCLC-NOS 6 (10.0)
Total dose, Gy
 <54 2 (3.3)
 54 14 (23.3)
 60 44 (73.3)
NSCLC-NOS, non–small-cell lung cancer not otherwise specified.
FIGURE 2.  Pattern of failures at initial recurrence. OS, over-
all survival; CS, cancer-specific survival; LC, local control.
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pulmonary disease in one patient; hepatocellular carcinoma in 
one; pulmonary tuberculosis in one; and cerebral hemorrhage 
in one. The OS and CSS rates at 2 and 5 years were 59.6% and 
61.7%, and 33.5% and 40.5%, respectively. Univariate analy-
ses were performed on the patient age, sex, performance sta-
tus, histology, total dose of radiation, the use of elective nodal 
irradiation, cT stage, and the tumor size for OS. The factors 
that showed a statistical significance on the 2-year OS rates 
included performance status (70.5% for ECOG 0–1, 40.3% 
for ECOG 2; p = 0.041), cT stage (87.5% for T1, 63.2% for 
T2, and 30.8% for T3; p = 0.002), tumor size (74.5% for tumor 
≤3 cm and 49.7% for tumor >3 cm; p = 0.011), and histology 
(63.3% for squamous cell carcinoma, 60.0% for adenocarci-
noma, and 33.3% for NSCLC-not otherwise specified [NOS]; 
p = 0.011). Multivariate analysis showed that high cT stage 
(p = 0.007) and histology with NSCLC-NOS (p = 0.008) were 
the significantly unfavorable prognostic factors for OS.
DISCUSSION
With the recent advances in the RT technique, SBRT, 
which has the advantages of high precision and accuracy, has 
been used more commonly in treating early-stage NSCLC.4–8 
The application of SBRT, however, is still challenging for 
the patients with centrally located or large-sized tumor, in 
fear of excessive toxicities.2,9 In addition, there are some 
occasions when the patients poorly tolerate SBRT that needs 
tight immobilization for a longer treatment time per each 
fraction. For these patients, more protracted hypofractionated 
regimens with shorter treatment time can be the alternative, 
based on the favorable clinical results and the acceptable 
FIGURE 3.  Overall survival, cancer-spe-
cific survival, and local control rate for 
all patients. ECOG, Eastern Cooperative 
Oncology Group.
FIGURE 4.  Local control rate according to (A), performance status, (B), cT stage, and (C) tumor size.
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toxicity profiles.12–17,19,20 At the author’s institute, definitive 
RT alone at 3.0 Gy per fraction has been used for the patients 
with early-stage NSCLC, who are not candidates for either 
surgery or SBRT. Herein, we have shown the favorable 
survival outcomes: 5-year OS and CSS rates of 33.5% and 
40.5%; and minimal toxicities. An excellent 2-year LC rate 
was achieved in cT1 tumors (100%), even though those for 
cT2 and cT3 tumors were not satisfactory (56.5% and 28.6%, 
respectively).
The treatment outcomes by more protracted hypofrac-
tionated RT schedules for early-stage NSCLC are summarized 
in Table 2. Soliman et al.15 reported the long-term results of 
RT with 48 to 60 Gy, using a daily fraction of 4 Gy for stage 
I to II NSCLC. Only 11 of 124 tumors were centrally located. 
The 5-year CSS and LC rates were 59.8% and 70.1%, respec-
tively. The 2-year LC rate was 82.5% for the tumors less than 
3 cm and 66.9% for the tumors of 3 cm or more. Milano et al.14 
treated 53 patients with 98 central lung lesions including stage 
I to III NSCLCs and metastatic lung tumors. RT was delivered 
with the median total dose of 50 (30–63) Gy in 2.5 to 5 Gy per 
fraction. The 2-year LC rate of all lesions was 73%. Bonfili et 
al.13 reported their results of RT with 60 Gy in 3 Gy per frac-
tion for the elderly patients with stage I to II NSCLC. Ten of 
36 patients had central tumors. The 2-year CSS and LC rates 
were 57.1% and 63.9%, respectively. Cancer and Leukemia 
Group B (CALGB) 3990412 prospectively evaluated the accel-
erated regimen for the patients with stage I NSCLC (<4 cm 
with pulmonary dysfunction). The dose per fraction was esca-
lated from 2.41 Gy to 4.11 Gy with the total dose of 70 Gy. 
Local failure occurred in three of 39 patients (7.7%).
Overall, the LC rate of approximately 60% to 70% 
was achieved when more protracted hypofractionated treat-
ment regimens were used for early-stage NSCLCs (Table 
2). The LC rate is thought to be lower when compared with 
SBRT, which may be because of insufficient total RT dose. 
Biologically effective doses (Gy
10
, α/β = 10) in most hypo-
fractionated regimens ranged from 70 to 85 Gy
10
, although 
biologically effective doses larger than 100 Gy
10
 are needed 
for improved LC.21,22 For the small tumors, however, hypo-
fractionated regimen also showed the excellent outcomes of 
the LC rate higher than 80%. In the current study, the 2-year 
LC rate was 100% for cT1 tumor, 56.5% for cT2 tumor, and 
28.6% for cT3 tumor, respectively. Despite limitations in small 
numbers of patients with cT1 tumors (n = 10), it is noted that 
there was only one local failure, which occurred in 34 months 
after a dosage of 54 Gy/18 fractions
.
The patients with centrally located tumors are not good 
candidates for SBRT, because of previously reported high risk 
of severe toxicities. Timmerman et al.2 reported that when 
SBRT was delivered with 60 to 66 Gy in three fractions, 14 
patients experienced grade 3 to 5 toxicities which included 
pneumonia, pleural effusion, apnea, skin reaction, pericardial 
effusion, massive hemoptysis, and decline in pulmonary 
function test. The authors showed that the probability of grade 
3 to 5 toxicities at 2 years was 46% for the central tumors 
and 17% for the peripheral tumors; however, they did not 
describe the difference in the toxicity profiles between the 
central and peripheral tumors and the reasons why the patients 
with central tumors experienced more toxicities. Naturally, 
the major airway is one of the most problematic organs at 
risk when SBRT has to be applied to the centrally located 
tumors. Mcgarry et al.23 reported one case of symptomatic 
bronchitis after SBRT of 60 Gy in three fractions and one case 
of tracheal necrosis after SBRT of 72 Gy in three fractions 
in a phase I dose-escalation study. Song et al.9 reported that 
complete or partial bronchial stricture developed in eight of 
nine patients (88.9%) who had central tumors, when treated 
with 40 to 60 Gy in three to four fractions. They also reported 
that one patient experienced death because of bleeding and 
two patients experienced grade 3 to 4 toxicity of bronchial 
stricture and secondary obstructive pneumonia. These major 
airway toxicities were sporadically reported even in the 
patients treated with conventional24,25 or hyperfractionated 
RT,26 and more often in the patients receiving endobronchial 
brachytherapy.27,28 The total irradiated dose to airway, which 
was higher than 80 Gy26 and dose per fraction27 might have 
been the significant risk factors for the airway toxicity. On 
the basis of the data published to date, it seems that more 
protracted hypofractionated regimens are associated with 
more acceptable toxicity profiles for the centrally located 
tumors. Milano et al.14 reported that fatal pulmonary toxicity 
occurred in four of 57 patients with central tumors, when 
treated with the median dose of 50 (30–63) Gy in 2.5 Gy to 
5.0 Gy per fraction. Two patients died from grade 5 dyspnea, 
one from bronchitis and one from fatal hemoptysis. According 
to the authors, all the patients who experienced fatal toxicity 
received multiple courses of RT. Bonfili et al.13 reported that 
no grade 3 or higher toxicity occurred when using 60 Gy in 
TABLE 2.  Recently Published Treatment Outcomes of Hypofractionated Radiation Therapy for Early-Stage Non–Small-Cell Lung 
Cancer
Study
Number 
of Patients 
(Lesions) Stage Location RT Regimen (TD/DD)
Biologically 
Effective Dose 
(α/β = 10) Local Control
Bonfili et al.11 36 Stage I–II Central, 10 peripheral, 26 60 Gy/3 Gy 78 Gy
10
63.9% at 2 yr
Soliman et al.13 118 (124) T1–3N0 Central, 13 peripheral, 111 48–60 Gy/4 Gy 67.2–84 Gy
10
76.2% at 2 yr 70.1% at 5 yr
Milano et al.12 53 (98) Stage I–III 
oligometastasis
Central, all 30–63 Gy/2.5–5 Gy  
(median 50 Gy/5 Gy)
Median 75 Gy
10
73.0% at 2 yr (all lesions)
Bogart et al.10 39 T1–2N0 Not mentioned 70 Gy/2.4– 4.11 Gy 86.9–98.8 Gy
10
92.3% (3 recurrences)
Present study 60 T1–3N0 Central, all 54–60 Gy/3 Gy 70.2–78 Gy
10
57.9% at 2 yr
DD, double drug; RT, radiation theraphy; TD, triple drug.
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3.0 Gy per fraction in 10 patients with the central tumors. 
Our data also showed acceptable toxicity. Grade 3 or higher 
toxicity developed in three patients (5.0%), one of whom died 
of radiation pneumonitis. Consequently, in the patients with 
the centrally located tumors, more protracted hypofractionated 
regimen ranging from 70 to 85 Gy
10
 may have reduced the 
incidence of severe toxicity including the major airway 
toxicity. Instead, the LC rate was lower than SBRT. A further 
dose escalation at no increased risk of severe toxicity will be 
needed to determine the therapeutic window. In our institute, 
a dose per fraction has recently been increased from 3.0 to 4.0 
Gy with a total dose up to 60 Gy.
Recently, risk-adaptive SBRT was applied to the cen-
trally located tumors.10 It showed that a 2-year LC rate of 85% 
and no grade 4 or 5 toxicity after SBRT to 63 patients with 
the central lung lesions, when the maximum dose in 0.5 cm3 
of the organs at risk was restricted to 6 to 7 Gy per fraction 
for the esophagus, 8 to 10 Gy for the trachea, and 8 to 12 Gy 
for the main bronchi. “Risk-adaptive” regimen indicates the 
SBRT dose modification with strict dose constraints for the 
critical structures. This approach should ideally be addressed 
in a prospective study to determine the optimal dose schedule 
in treating the central lung tumors. The ongoing trial of SBRT 
for centrally located tumors (RTOG 0813) is expected to give 
us further evidence on this issue.
In conclusion, hypofractionated RT using 3.0 Gy per 
fraction to centrally located cT1-3N0 NSCLC proved safe 
with minimal toxicity, and, based on the excellent clinical out-
comes in cT1 tumors, might serve as an alternative option for 
patients who might not tolerate SBRT. The clinical outcomes 
in cT2–3 tumors, however, were still unsatisfactory, and fur-
ther dose-intensifying regimen coupled with the use of con-
current systemic chemotherapy might be warranted.
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